Abstract: The present disclosure provides a flexible display module and a method for manufacturing the flexible display module. The flexible display module includes a flexible display panel, a driving chip and a circuit board. The flexible display panel includes a display region and a bonding region, and the driving chip and the circuit board are arranged at the bonding region. The circuit board includes a first flexible printed circuit and a first printed circuit board provided with an electronic element, the first printed circuit board is coupled to one end of the first flexible printed circuit, and the first flexible printed circuit includes a bonded portion coupled to the bonding region of the flexible display panel. The first flexible printed circuit is bent so that a first space is defined by the first flexible printed circuit, the first printed circuit board and the flexible display panel.

Abstract: In a network congestion handling method, a first network device determines a target port, where the target port is an egress port that is in a pre-congestion state or a congestion state. The first network device sends a first notification to at least one second network device. The at least one second network device is capable of sending, through at least two forwarding paths, a data flow to a host corresponding to the target port. The first notification includes information of a network device to which the target port belongs and information of the target port. The first notification can enable the at least one second network device to perform an operation of avoiding network congestion. The network congestion handling method can effectively alleviate network congestion and improve network bandwidth utilization.

Abstract: The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker, respectively; wherein the payload A and the payload B are the same or different. A pharmaceutical composition comprises the immunoconjugate and a method for treating cancer are also provided in the disclosure.

Abstract: A processing method for preventing electromagnetic induction when a main system and a standby system of a safety drive unit co-drive a relay. The method includes the following steps: periodically acquiring and detecting a drive command; detecting a port state of an output port of a safety drive unit when the drive command changes; performing a corresponding processing operation according to the port state of the output port; and repeating the foregoing steps.

Abstract: A method and system for text-to-video generation. The method includes receiving a text input, generating a representation frame based on the text input using a model trained on text-image pairs, generating a set of frames based on the representation frame and a first frame rate, interpolating the set of frames to a higher frame rate, generating a first video based on the interpolated set of frames, increasing a resolution of the first video based on a first and second super-resolution model, and generating an output video based on a result of the super-resolution models.

Abstract: Disclosed is a method for preparing a nano-porous carbon material, comprising the following steps of: mixing polypyrrole nano-fibers with an activator, conducting microwave heating for reaction, and purifying to obtain the nano-porous carbon material. Compared with a conventional high-temperature carbonization method, the method for preparing the nano-porous carbon material of the present disclosure is simple in raw material, convenient to operate, less in time consumption and more suitable for mass preparation and production of the nano-porous carbon materials.

Abstract: Disclosed is a high-precision dynamic real-time 360-degree omnidirectional point cloud acquisition method based on fringe projection. The method comprises: firstly, by means of the fringe projection technology based on a stereoscopic phase unwrapping method, and with the assistance of an adaptive dynamic depth constraint mechanism, acquiring high-precision three-dimensional (3D) data of an object in real time without any additional auxiliary fringe pattern; and then, after a two-dimensional (2D) matching points optimized by the means of corresponding 3D information is rapidly acquired, by means of a two-thread parallel mechanism, carrying out coarse registration based on Simultaneous Localization and Mapping (SLAM) technology and fine registration based on Iterative Closest Point (ICP) technology.

Abstract: A vacuum apparatus includes process chambers, and a transfer chamber coupled to the process chambers. The transfer chamber includes one or more vacuum ports, thorough which a gas inside the transfer chamber is exhausted, and vent ports, from which a vent gas is supplied. The one or more vacuum ports and the vent ports are arranged such that air flows from at least one of the vent ports to the one or more vacuum ports are line-symmetric with respect to a center line of the transfer chamber.

Abstract: Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-?), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and ?-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG, purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.

Abstract: A device-verification system is configured to verify the authenticity of an electronic device using a digital signature of the electronic device verified by a certificate authority. In some examples, the electronic device includes a NFC tag storing device hardware information, device public and private keys, and a device digital signature ciphertext. A user may utilize a personal device to read the information from the NFC tag and the personal device may include a software application configured to communicate the information to a cloud-based certificate authority. The certificate authority may include a distributed system (e.g., a blockchain ledger) utilized to verify, store, and subsequently retrieve data corresponding to the electronic device. The certificate authority is configured to utilize the device digital signature to verify the authenticity of the device.

Abstract: A semiconductor device includes: a cell region including active regions where components of transistors are formed; the cell region are arranged to function as a D flip-flop that includes a primary latch (having a first sleepy inverter and a first non-sleepy (NS) inverter), a secondary latch (having a second sleepy inverter and a second NS inverter), and a clock buffer (having third and fourth NS inverters). The transistors are grouped: a first group has a standard threshold voltage (Vt_std); a second group has a low threshold voltage (Vt_low); and an optional third group has a high threshold voltage (Vt_high). The transistors which comprise the first or second NS inverter have Vt_low. Alternatively, the transistors of the cell region are further arranged to function as a scan-insertion type of D flip-flop (SDFQ) that further includes a multiplexer; and the transistors of the multiplexer have Vt_low.

Abstract: Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-?), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and ?-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG; purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.

Abstract: In a method, a structure including two or more materials having different coefficients of thermal expansion is prepared, and the structure is subjected to a cryogenic treatment. In one or more of the foregoing and following embodiments, the structure includes a semiconductor wafer and one or more layers are formed on the semiconductor wafer.

Abstract: Disclosed are a novel rotation control system and method for an excavator. The novel rotation control system comprises a controller, an electrical control handle, an instrument, a rotating motor, a rotating valve trim, a main pump, a first electromagnetic valve, a second electromagnetic valve, a first pilot pressure sensor, a second pilot pressure sensor, an overflow valve and a one-way valve, and further comprises a rotation sensor used for detecting whether an excavator is rotating, a regulator used for controlling the displacement of the main pump, and a temperature sensor used for monitoring the temperature of hydraulic oil in real time.

Abstract: Provided herein are metabolically-modified microorganisms that can grow on an organic C1 carbon source.

Abstract: A sensing electronic device includes a substrate, and a reference voltage control unit. The sensing array is arranged on the substrate, and includes a first sensing electrode and a second sensing electrode. The reference voltage control unit is electrically connected to the sensing array. In an operation period, the reference voltage control unit has a first voltage, the first sensing electrode has a second voltage, and the second sensing electrode has a third voltage, wherein a difference between the first voltage and the second voltage is different from a difference between the first voltage and the third voltage.

Abstract: An electronic device is provided. The electronic device includes a substrate, an optical sensing element, a light-shielding structure, and a microlens. The substrate has a normal direction. The optical sensing element is disposed on the substrate. The light-shielding structure is disposed on the optical sensing element and includes a plurality of light-shielding layers. Each light-shielding layer includes an opening, and centers of the openings are arranged along a first direction and separated from each other. The microlens is disposed on the light-shielding layers and overlaps the opening of the uppermost light-shielding layer. The microlens guides light into an optical channel formed by the openings, so that the optical sensing element has a maximum response value for light with an incident angle that is greater than or equal to 10 degrees and less than or equal to 30 degrees relative to the normal direction.

Abstract: A luminal stent has a tube body and a skirt surrounding the tube body. The skirt has a flexible connecting section and a stent graft connected to a proximal end of the flexible connecting section. A distal end of the flexible connecting section is sealed and connected to the outer surface of the tube body. A proximal end of the stent graft is suspended and provided with a first radial support structure. When the flexible connecting section is radially compressed, at least a part of the first radial support structure is bent towards a direction distant from the tube body. Also provided is a stent system including the luminal stent. The stent system and the luminal stent can prevent type III endoleaks.

Abstract: Compositions and methods for reprogramming glial cells into neurons are provided. The method entails using a combination of insulin and forskolin generate neurons. The neurons may be generated by converting glial cells into the neurons. The compositions and methods may also include one or both of Vitamin C (VC) and Crizotinub (Cri). Articles of manufacture are provided which include at least one pharmaceutical formulation, packaging, and printed material providing an indication and/or instruction for using the described compounds.

Abstract: An apparatus includes a chamber, a pedestal configured to receive and support a semiconductor wafer in the chamber, and an edge ring disposed over the pedestal. The edge ring includes a first portion having a first top surface, a second portion coupled to the first portion and having a second top surface lower than the first top surface, and a recess defined in the first portion. The second top surface is under the semiconductor wafer. The recess has a depth, and a distance between the pedestal and an inner surface of the recess is substantially equal to the depth of the recess.